Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has said that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that company's Lipitor or atorvastatin enantiomer patent is invalid.
Subscribe to our email newsletter
The patent had been challenged by generics manufacturer Ranbaxy and expires in July 2010. The decision has no commercial impact because company’s basic patent covering Lipitor remains in force and expires in November 2011. The company also said that the same court has ruled that the basic patent would be infringed by Ranbaxy’s proposed generic atorvastatin product. That decision, which is also subject to possible appeal, prevents Ranbaxy from launching a competitor drug before November 2011.
Pfizer pointed out that this ruling does not affect patent litigation involving Lipitor in other jurisdictions, including the US. It also said it will continue to vigorously defend its patents against infringement.